Lee, Kyung-min http://orcid.org/0000-0001-8381-2423
Guerrero-Zotano, Angel L. http://orcid.org/0000-0003-0318-9120
Servetto, Alberto
Sudhan, Dhivya R.
Lin, Chang-Ching
Formisano, Luigi
Jansen, Valerie M.
González-Ericsson, Paula http://orcid.org/0000-0002-6292-6963
Sanders, Melinda E.
Stricker, Thomas P.
Raj, Ganesh
Dean, Kevin M. http://orcid.org/0000-0003-0839-2320
Fiolka, Reto http://orcid.org/0000-0002-4636-5000
Cantley, Lewis C. http://orcid.org/0000-0002-1298-7653
Hanker, Ariella B. http://orcid.org/0000-0002-8655-8341
Arteaga, Carlos L. http://orcid.org/0000-0003-0870-9586
Article History
Received: 19 March 2020
Accepted: 6 October 2020
First Online: 30 October 2020
Competing interests
: C.L. Arteaga has received research grants from Pfizer, Lilly, and Takeda. He holds minor stock options in Provista and Y-TRAP, and serves or has served in an advisory role to Novartis, Merck, Lilly, Daiichi Sankyo, Taiho Oncology, OrigiMed, Puma Biotechnology, Immunomedics, AstraZeneca, and Sanofi. He is a member of the Scientific Advisory Board (SAB) of the Susan G. Komen Foundation. L.C. Cantley is a founder and member of the SAB and holds equity in Agios Pharmaceuticals and Petra Pharmaceuticals, companies developing drugs for treating cancer. The laboratory of L.C. Cantley also receives funding from Petra. A.B. Hanker receives grant support from Takeda. A.L. Guerrero-Zotano has received grant support from Pfizer and travel support from Pfizer and Roche. V.M. Jansen is a current employee and shareholder of Eli Lilly and Company.